Surgical Immunology for Surgeons — Stress Response, SIRS/CARS, Sepsis Immunity, Steroids, Anaphylaxis, Tumour Immunity

The surgeon does not prescribe immunotherapy and does not run the flow cytometer — but the surgeon times the operation in the immunosuppressed host, recognises the two-phase immune trajectory after major surgery, suspects adrenal crisis in unexplained hypotension, treats anaphylaxis before the rash appears, and understands why the cancer operation itself can seed what it seeks to cure. Learn surgical immunology as operative doctrine: major surgery produces generalised immediate immunosuppression; its severity tracks trauma extent, underlying disease, infection and nutrition; early pro-inflammatory SIRS is followed by anti-inflammatory CARS; imbalance causes organ dysfunction while protocols and damage control — not cascade drugs — cut complications; monocyte HLA-DR depression marks danger without guiding therapy; sepsis is a balance race needing phase-matched treatment; steroids cover true insufficiency without blanket supplementation; epinephrine precedes diagnosis in anaphylaxis; and tumour-draining nodes coordinate the very immunity the scalpel removes.^{[4][2][3][11][18][19][34][38][40]}

A day-14 septic laparotomy patient who cannot wean, a steroid-dependent colitis patient booked for colectomy, a rheumatic on biologics needing a hernia repair, an induction collapse after muscle relaxant, and a node-positive cancer where the oncologist asks about counts all sit on the same teaching list. The examiner will ask for the stress-response mediator set, the innate-adaptive bridge, the M1/M2 ledger, the SIRS-to-CARS sequence with its Bone coinage, the first-hit/second-hit frame, why MODS has no rescue drug, what PICS replaced, what HLA-DR depression means, how sepsis endotypes change therapy, which abdominal-sepsis markers are routine, what the DAMP window forbids, which periop drugs continue and which pause, the steroid numbers with their humility clause, the anaphylaxis order with its odds ratios, and where nodal equipoise now lies. This page answers each question with every statement taken from the paper named beside it.^{[1][26][29][15][11][17][23][24][32][35][39][40]}

Stress Response — the Kehlet Doctrine

Major surgery still brings pain, cardiopulmonary, infective and thromboembolic complications, cerebral dysfunction, nausea and gastrointestinal paralysis, fatigue and prolonged convalescence.^[1] Excluding technique failures, the key pathogenic factor behind that morbidity is the surgical stress response with its increased demands on organ function.^[1] Organ-function change runs through trauma-induced endocrine-metabolic shifts plus cytokines, complement, arachidonic-acid metabolites, nitric oxide and free oxygen radicals.^[1] No single technique or drug regimen has been shown to eliminate postoperative morbidity and mortality — only multimodal intervention promises major reduction with better recovery and lower overall costs.^[1]

Severity is proportional: immune disorder after surgery scales with trauma extent and turns on the underlying disease (notably cancer), coexisting infection and nutritional status.^[2] Disordered immunity after surgical trauma predisposes to septic complications carrying the highest mortality rate.^[2] In cancer surgery the picture is simultaneous pro- and anti-inflammatory activation — SIRS alongside CARS — with a general belief in sustained postoperative immunosuppression that promotes both sepsis and tumour proliferation with metastasis.^[2]

Laparoscopy, Anaesthesia, Autonomic Balance — Levers on Suppression

Laparoscopic surgery means less trauma and therefore a smaller acute-phase response than open surgery.^[5] That matters because immune impairment can enhance surgical infections, port-site metastases and sepsis.^[5] Systemically, delayed-type hypersensitivity and lymphocyte-antigen endpoints show preserved immune function after laparoscopy versus conventional surgery — yet carbon dioxide pneumoperitoneum attenuates local peritoneal immunity, lowering tumour-necrosis-factor production and macrophage phagocytic capacity.^[5] Less suppression, not none: the honest formulation is lower systemic stress with a locally quieted peritoneum.^[5]

Regional anaesthesia suppresses cortisol and catecholamine levels and reduces postoperative muscle breakdown, carries less immunosuppressive effect, and may dampen the pro-inflammatory cytokine response — with brain and kidney function possibly better preserved, though further study is needed.^[6] The volatile warning reads carefully: volatile general anaesthetics appear to promote cancer malignancy versus regional and intravenous techniques by suppressing natural-killer-cell anti-cancer capacity — but the same review states evidence is insufficient to change current practice, and that humility is the examinable point.^[6]

Autonomic imbalance — sympathetic hyperactivation with low parasympathetic tone — occurs perioperatively and drives stress responses, cardiovascular instability, impaired tissue repair and immunosuppression, raising infection, neurocognitive-decline and multiorgan-dysfunction risk.^[7] Trauma, anaesthesia, pain, hypothermia and psychological stress all feed the dysregulation, and low parasympathetic tone leaves the cholinergic anti-inflammatory pathway less effective, while high sympathetic activity surges catecholamines with pro-inflammatory cytokine release.^[7] Restoring balance is framed as an important perioperative prospect for short- and long-term recovery — a target under study, not a prescription.^[7]

Neuroimmune Control — the Brain Depresses Immunity

Pro-inflammatory cytokines stimulate the hypothalamic-pituitary-adrenal axis and enhance sympathetic activity, and those neuroimmune mediators suppress immune-cell function to contain systemic inflammation.^[8] The trap: the same inhibitory pathways firing without systemic inflammation — brain cytokines after infection, injury or ischaemia, life-event or affective stressors, even brainstem irritation — generate brain-mediated immunodepression.^[8] Monocytes are the newly recognised fulcrum: monocytic inactivation with lost antigen presentation and depressed pro-inflammatory secretion raises infectious-complication risk.^[8] Catecholamine-driven interleukin-10 release is the newly discovered monocyte-deactivation mechanism beside the well-known glucocorticoid effect.^[8] The anti-inflammatory starter set itself — interleukin-10, interleukin-1-receptor antagonist, soluble tumour-necrosis-factor receptors — is what initiates CARS after cytokines finish their early useful work.^[8]

Innate Meets Adaptive — One System, a Ladder, a Platform

Innate and adaptive responses are interacting components of one system supplying complementary information — context from innate, specificity from adaptive — and coordination of the two is vital for effective responses.^[26] The central handshake is dendritic cell to naive T cell, the sole route of naive-T activation: a dendritic cell activated by pathogen- or damage-derived molecules expresses co-stimulation and secretes directing cytokines, and its phenotype — set by its own environmental encounters — decides the T-cell outcome.^[26] Complement belongs on both sides: pathogen-surface cascade defence plus classical-pathway humoral membership through B-cell activation, affinity maturation and memory.^[26]

The presentation ladder runs in six discrete steps from antigen acquisition through degradation-tagging to peptide-MHC display for T-cell recognition.^[27] Processing and presentation are the cornerstones of adaptive immunity: CD4 T cells use antigen-specific receptors reading peptide cargo on MHC, and the two glycoprotein classes split the work — MHC-I to CD8, MHC-II to CD4 — while B cells cannot make high-affinity antibody without T-cell help.^[27] Fifty years of HLA-disease association makes HLA the fundamental surveillance-and-responsiveness platform in health and disease, with personalised antigen-specific prevention through HLA-ligand harnessing becoming a realistic prospect — awareness to carry, not assays this topic orders.^[28]

Macrophages — Polarization and Orderly Stages

Macrophages are heterogeneous, their phenotype and function set by the surrounding micro-environment, and they sit stationed through body tissues ingesting foreign material, dead cells and debris while recruiting reinforcements to inflammatory signals.^[29][30] The two-subset ledger: LPS- or Th1-polarised pro-inflammatory M1 (interferon-gamma, GM-CSF drivers; interleukin-1beta, IL-6, IL-12, IL-23, TNF-alpha products) versus IL-4/IL-13-polarised anti-inflammatory immunoregulatory M2 (IL-10, TGF-beta products) — and the M1/M2 balance governs organ fate in inflammation or injury.^[29] M2 then secretes high IL-10 and TGF-beta to suppress inflammation and drive repair, remodelling, vasculogenesis and homeostasis — while a stuck M1 phase destroys tissue.^[29]

Orderly inflammation walks four stages: tissue recruitment, in-situ differentiation and activation, conversion to suppressive cells, restoration of homeostasis.^[30] Macrophage subsets then play protective and pathogenic parts across antimicrobial defence, anti-tumour immunity, allergy, autoimmunity, atherosclerosis, fibrosis and wound healing — rapid function-switching on local signals, with human-heterogeneity characterisation still in progress.^[30] The viva discipline: quote polarization as a compass for where the patient sits on the four-stage walk, never as a bedside assay.^[29][30]

Cytokines and Mediators — the Surgeon's Cascade Map

Tissue injury and infection disturb metabolic and immune homeostasis through mononuclear-phagocyte endogenous mediators — the cytokines mediating host response — with TNF and interleukin types 1 and 6 prominent in infection and trauma.^[9] Those mediators start as provisioning: integrated fuel-substrate and hormonal adjustment giving systemic defences optimal metabolic homeostasis.^[9] Past a threshold they turn pathogenic: widespread injury, especially with fulminant sepsis, massively releases TNF, IL-1 and IL-6 across multiple organs into the sepsis syndrome.^[9] Endotoxin-neutralising and cytokine-blocking therapies of that era held promise but required careful benefit-versus-complication evaluation before widespread use — the original humility clause on cascade drugs.^[9]

The wider network: severe-trauma stimuli include neutrophil tissue-damaging substances, complement activation products and selectin adherence molecules, and the shocked gut is the intermediate step from non-infectious to infectious SIRS.^[10] Sepsis-phase mediators add nitric oxide, phospholipase A2, platelet-activating factor and procoagulants — with release depending first on trauma, shock or sepsis severity and only second on cascade activation, deciding organ-damage intensity and outcome.^[10]

In surgical infection the cascades are concrete: plasma LPS exposure forms bradykinin, fires the kallikrein-kinin system and consumes kallikrein-inhibitor capacity, while coagulation, fibrinolysis and complement cascades activate together.^[14] Peptidoglycan releases TNF-alpha, IL-1beta and IL-6 from macrophages with pro- and anti-inflammatory gene activation; clinically, plasma LPS tracks multiple organ dysfunction and failure with systemic cytokine release — the basis on which the authors built early-infection monitoring.^[14]

Complement — Surveillance With an Inhibitor Horizon

Complement activation sits inside the pathogenesis of many human diseases, so pharmacologic inhibition should suppress complement-mediated processes — with plasma-derived high-molecular-weight natural inhibitors and recombinant membrane regulators as the two development tracks.^[25] The established beachhead is plasma C1-esterase-inhibitor concentrate for hereditary angioneurotic oedema; C1-INH is consumed in severe inflammation with reported benefit signals in human sepsis, post-operative reperfusion myocardial dysfunction, post-marrow-transplant capillary leak, lung-transplant reperfusion injury, burns and IL-2-therapy cytotoxicity — signals, never orders.^[25] Recombinant soluble CR1 versions suppress ischaemia-reperfusion injury, thermal trauma and immune-complex inflammation experimentally while human trials are still awaited; transgenic-organ resistance to hyperacute rejection with persisting acute vascular rejection keeps xenotransplantation on the horizon rather than the list.^[25] Gene-variant complement blockade, DSA-C1q stratification and transplant complement protocols belong to nephrology and transplant topics — this topic owns only the bridge lesson of [26].^[26]

SIRS to CARS — the Two-Phase Doctrine

Innate immunity can fire without microbes: ischaemia- and necrosis-derived internal danger signals suffice.^[13] Severe enough activation propels the host's own response into SIRS, MSOF and shock — and most survivors of the first insult then face secondary or opportunistic infection through CARS.^[13] CARS anatomy is macrophage deactivation, T-cell anergy and rapid apoptotic loss of lymphoid tissue, and early anti-cytokine SIRS-directed trials disappointed precisely because they ignored this second phase.^[13]

Bone's 1997 coinage defines CARS as the counter-regulation limiting overzealous inflammation in infectious or non-infectious SIRS.^[15] Its price is nosocomial susceptibility in intensive-care patients.^[15] Its nature is reprogramming, not ruin: circulating leukocytes alter function without global defect, tissue leukocytes stay primed or activated, and the response reads as adapted and compartmentalised — silencing acute pro-inflammatory genes while preserving anti-infectious ones.^[15] The one-line contrast the viva wants: SIRS activates immunity to kill organisms, CARS deactivates immunity to restore homeostasis — and timing plus relative magnitude decide outcome.^[16]

Trauma — First Hits, Second Hits, Monocytes

Early trauma death comes from brain injury and blood loss; late death comes from secondary brain injury and host-defence failure.^[11] First hits (hypoxia, hypotension, tissue and fracture injury) plus second hits (ischaemia-reperfusion, compartments, operations, infections) trigger the SIRS mediator release, with parallel anti-inflammatory mediators forming CARS — and imbalance between the two drives organ dysfunction with infection susceptibility.^[11] The trial paradox is examinable: anti-inflammatory, anti-coagulant and antioxidant trials mostly failed, while pre- and in-hospital protocols with damage-control principles cut complications — so the doctrine is wise operations plus immunomonitoring to pick at-risk patients, not blind cascade blockade.^[11] Resuscitation fluids, pressures and transfusion triggers stay fenced to shock, trauma and transfusion topics; only the immune-balance frame is claimed here.^[11]

Monocytes run the early phase: post-trauma SIRS is mediated by circulating monocytes with innate components before pathogen-limited acquired immunity preponderates, then CARS quenches the fire with anti-inflammatory mediators.^[12] The regulation is precise and fragile — deviation means multiorgan failure and death.^[12] Deviant patterns (excessive inflammatory monocytes, premature or exorbitant CARS, blood macrophage predominance, dendritic depletion) build MOF in trauma patients without accompanying sepsis.^[12]

Cell Response, PICS, Monocyte Watch — Why the ICU Stay Lengthens

Major surgery's early SIRS — pro-inflammatory cytokines, microcirculatory disturbance, cell-mediated dysfunction — is followed by CARS inviting opportunistic infection, MODS and death; with no effective MODS treatment, prevention starts early.^[3] Experimental candidates (interferon-gamma, G-CSF, PGE2 blockade with indomethacin, pentoxifylline) aim to redress the pro/anti cell imbalance — candidates, never prescriptions.^[3] The stakes triad: surgery-plus-anaesthesia gives generalised immediate immunosuppression through metabolic-endocrine responses, implicated in septic complications and metastasis formation, with adjuvant-treatment effectiveness depending on a functioning immune system — so minimising suppression is oncologic as well as infective strategy.^[4]

Beyond about ten days the phenotype changes name: the experienced intensivist's complicated clinical course is persistent immune dysfunction, and modern care increasingly delivers survivors of sepsis or surgery into persistent inflammation, immunosuppression and catabolism syndrome — PICS — which has replaced late MOF as the dominant prolonged-ICU pathophysiology, usually with poor outcome.^[17] These patients shuttle between long-term care and ICU and rarely reach self-sufficiency; therapy means immune rebalance with nutritional and physical rebuilding.^[17] The SIRS-then-CARS framework still describes the transit of severe sepsis, trauma and emergency abdominal sepsis — but why dysfunction persists remains unexplained.^[17]

The bedside watch is monocytic: a subset of trauma, major-surgery and sepsis patients develops hyporesponsive innate defences with infection and death risk.^[18] The defect spectrum runs from altered cytokine responses — notably depressed ex-vivo TNF production — to failed antigen presentation as depressed HLA-DR expression, the commonest-described marker of secondary infection and death.^[18] Endotoxin tolerance and monocyte impairment are studied as one entity with microRNA biomarkers emerging and a reliable human model still missing.^[18] Monocyte impairment predicts nosocomial infection, MOF and death in some surgical patients — yet no early high-risk marker is proven, and none guides therapy.^[18]

Sepsis Immunity — Balance, Endotypes, Atypical Hosts

Sepsis is a race to the death between pathogens and host immunity, and the pro/anti-inflammatory balance decides the individual outcome.^[19] The field's highly touted trial failures taught the lesson: progress needs pathophysiologic understanding of both pathways, with biomarker-guided immunotherapy delivered at the correct immune phase as the potential major advance.^[19] The modern correction: hyperinflammation and suppression run simultaneously rather than sequentially, endotypes split distinct immune profiles with distinct outcomes, and the gut microbiome shapes sepsis immunity — so translation means stratified therapy, with molecular-to-outcome translation still the coming-years challenge.^[20]

The current definition anchors the viva: dysregulated host response to infection causing life-threatening organ dysfunction, with the insult variably activating and suppressing multiple body systems.^[21] Susceptibility spans pathogen load and virulence, infection site, genetics, biological variability, comorbidities, immunosuppression, age extremes, deprivation and environment — and that variability demands individualised, biomarker-guided targeted intervention.^[21] Sepsis management detail (bundles, fluids, pressors, antimicrobials) stays fenced to sepsis and shock topics; this topic owns only the immune-balance frame.^[21]

Two surgeon-facing edges complete the picture. Intra-abdominal sepsis — the second source after pneumonia, worse for its polymicrobial multiplicity — is treated by early recognition, source control, appropriate antibiotics and ICU stabilisation with excellent surgery.^[23] Its diagnostic workhorses are white-cell count, CRP and procalcitonin, while TNF-alpha, IL-6, HMGB1 and presepsin show high diagnostic efficiency without routine use — studied, not ordered.^[23] And the immunocompromised septic breaks the pattern: immunosuppression is an infection-and-sepsis risk factor, yet the specific derangement in any individual is often unclear, presentation runs atypical with differing tests, early recognition is hard — and trial inclusion of these patients is crucial rather than optional.^[22]

DAMPs and SAMPs — the Homeostatic Window

Controlled DAMP and SAMP production restores homeostasis and repair after tissue injury — so only pathological concentrations merit therapy.^[24] Each context needs its homeostatic DAMP:SAMP ratio and window defined before treatment, to keep the modality safe.^[24] The design matrix: inhibit DAMPs in hyperinflammation such as SIRS, give SAMPs in chronic inflammation, inhibit SAMPs in hyper-resolution such as CARS, induce DAMPs for vaccines and anti-cancer therapy — principle, never formulary.^[24] Why surgeons care: sterile operative injury speaks the same danger language as infection, and the window separates healing inflammation from disease.^[24]

Immunocompromised Periop — Recognition, Rheumatic Rules, Steroid Verdict

Optimal care of the immunocompromised surgical patient starts from disease-specific drug toxicities — cardiac, pulmonary, hepatic, genitourinary, neurologic, marrow, skin, mitochondrial, lipodystrophy, hypersensitivity and liver effects — which strongly shape periop decision algorithms across cancer, HIV and transplant hosts, with corticosteroids, calcineurin inhibitors, sirolimus and antimetabolites as the named awareness set.^[31] Cancer immunocompromise adds its own triad — neutropenia, lymphopenia, immune impairment — compounded by periop corticosteroids, cytotoxics and immunotherapy into more complications and worse cancer outcomes.^[33] Drug dosing, holds and bridges belong to pharmacology, transplant and disease topics; recognition and referral are owned here.^[31][33]

Rheumatic disease brings three deliberations — cardiovascular risk, immunosuppressive drugs, altered coagulation — under an explicit lack of evidence-based recommendations.^[32] The current suggestions: follow cardiology guidance with the rheumatic disease as risk modifier; continue conventional DMARDs (neutral periop effect, no need to stop); minimise periop steroids and unnecessary steroid preps; balance biologic-stop benefit against flare risk; and bridge antiphospholipid syndrome as high periop-thrombosis risk per chest-physician guidance.^[32]

Steroids carry the topic's sharpest verdict. The Association of Anaesthetists, Royal College of Physicians and Society for Endocrinology guideline exists to identify adrenal insufficiency and supplement it perioperatively: primary gland failure versus secondary pituitary or hypothalamic failure, stress-dose hydrocortisone mandated for true replacement-treated insufficiency, chronic glucocorticoids (prednisolone 5 mg or more daily for a month or more by any route including inhaled, nasal, articular or topical) as the commonest suppression cause, replacement dosing on top of usual steroids with no blanket recipe, and vigilance because undiagnosed insufficiency sometimes first presents under surgical stress.^[34] Against that stands the systematic review: no periop-steroid guideline for exposed non-cardiac non-transplant patients exists, corticosteroids bring hyperglycaemia, infection and poor healing, and the entire randomised base is two trials totalling 37 patients with five cohorts and four reviews — showing no difference and permitting no conclusion either way.^[35] The practice synthesis: supraphysiologic cover was standard for six decades but accumulating data suggest it is unnecessary — stay on baseline maintenance and suspect secondary insufficiency in unexplained periop hypotension.^[36] The viva answer holds both: cover the truly insufficient, do not blanket-supplement, and state the numbers that force the humility.^[34][35][36]

Perioperative Anaphylaxis — Recognise, Epi-First, Work Up

Perioperative anaphylaxis is life-threatening and under-recognised, most commonly triggered by antibiotics, neuromuscular blockers, dyes, latex and disinfectants.^[37] Presentation is hypotension, tachycardia and bronchospasm — the common triad that is nonspecific, which is exactly what makes diagnosis hard.^[38] Supporting factors are onset timing, vasopressor-unresponsiveness, severe hypovolaemia and rash appearance — but treatment never waits for skin findings, because haemodynamic compromise is often the whole presentation.^[38] The order is fixed: epinephrine, fluids, airway, remove triggers — with provider vigilance and a high index of suspicion as the stated safety requirements.^[38] Definitive culprit workup with comprehensive allergy evaluation follows recovery.^[37]

Risk maths comes meta-analytic: across 19 studies with 672 anaphylaxis episodes, 5,608 immune-mediated reactions and 1,126 severe episodes, drug allergy (odds ratio 3.54), food allergy (2.29), any allergy history (4.86) and atopy (3.58) raise periop-anaphylaxis incidence — but not immune-mediated-reaction rates and not severity.^[39] A prior drug or food allergy, any allergy history, or atopy makes periop anaphylaxis more likely without predicting a worse reaction — and whether allergy history is a major confounder-controlled factor still needs study.^[39]

Surgical Tumour-Immunity and Nodal Preservation — the Synthesis

Resection can seed what it removes: accumulating evidence suggests surgical stress triggers the post-operative metastatic niche.^[41] The mechanism ledger: sympathetic-adrenomedullary plus hypothalamic-pituitary-adrenocortical activation with hypoxia and a hypercoagulable state, downregulating neutrophils, macrophages, NK cells and cytotoxic T lymphocytes while upregulating regulatory T cells and myeloid-derived suppressor cells toward niche colonisation and progression.^[41] Surgery is now proven as a risk factor promoting dormant micrometastases and accelerating new ones through neuroendocrine-stress hormones plus wound-healing immunosuppression, neovascularisation and remodelling — consequences acting synergistically — with tumour-associated neuroglial contributions recognised but mechanistically still unclear.^[42] The countermeasure hierarchy stays surgical: safe minimally invasive surgery is the best oncotaxis control, autonomic balance is the emerging target, and experimental cytokine-storm or oxygen-radical scavenging stays out of this topic's prescribing.^{[5][7][41][42]}

The nodal question is genuine equipoise. Contemporary immunology reframes tumour-draining lymph nodes as active co-ordinators of anti-tumour immunity, and routine lymphadenectomy may theoretically impair systemic surveillance and checkpoint-inhibitor response — most relevant in mismatch-repair-deficient, MSI-high disease.^[40] Yet retrospective colorectal datasets still show better survival with bigger nodal yield, with causality unproven and confounded by tumour biology, surgical quality and centre volume; preclinical work keeps nodes essential for systemic immunity and ICI effectiveness with early human adjuvant signals.^[40] The defensible position: balance oncological clearance against immune preservation through selective sentinel or tracer-guided nodal surgery inside stratified dMMR/MSI-H-versus-MSS trials — technique to colorectal and breast topics, regimens to oncology, hypothesis framing owned here.^[40]

Exam Synthesis and Fence Map — What This Topic Owns

This topic owns surgeon-facing immunology: Kehlet stress doctrine with multimodal-only reduction; proportionality to trauma, disease, infection and nutrition; laparoscopy-preserved systemic with locally quieted peritoneal immunity; regional-anaesthesia cortisol, catecholamine and NK endpoints with volatile humility; autonomic sympathetic-versus-cholinergic balance; brain-mediated HPA, sympathetic and IL-10 monocyte depression; TNF, IL-1 and IL-6 provisioning-to-sepsis-syndrome arc with cascade-drug caution; neutrophil, complement, selectin, nitric-oxide, phospholipase-A2, platelet-activating-factor and procoagulant networks with severity-first release and shocked-gut transition; LPS kallikrein-kinin with coagulation, fibrinolysis and complement co-activation plus plasma-LPS monitoring; Bone 1997 CARS coinage with reprogramming-not-defect compartmental doctrine and timing-magnitude outcome rule; trauma first-hit/second-hit imbalance with failed-trial versus damage-control paradox; monocyte SIRS-to-CARS fragility; early-SIRS-then-CARS cell response with MODS-prevention and experimental-candidate framing; generalised immediate post-op immunosuppression with sepsis, metastasis and adjuvant stakes; ten-day PICS replacement of late MOF with rebalance-plus-rebuilding therapy; HLA-DR-centred monocyte watch with therapy-guidance humility; Hotchkiss balance race with phase-matched immunotherapy horizon; simultaneous hyperinflammation-suppression with endotype stratification; dysregulated-activation-and-suppression sepsis definition with individualised biomarker treatment; immunocompromised atypical presentation with trial-inclusion imperative; abdominal-sepsis workhorse-versus-studied marker split; DAMP:SAMP homeostatic-window matrix; C1-INH beachhead with sCR1 horizon; innate-adaptive single-system handshake with dendritic-T fate decision and complement humoral membership; six-step MHC-I/MHC-II ladder with HLA surveillance platform; M1/M2 cytokine ledger with four-stage orderly inflammation; immunocompromised drug-toxicity awareness with DMARD-continue, steroid-minimise, biologic-balance and APS-bridge rules; steroid cover-the-insufficient with 5-mg suppression threshold, 37-patient evidence base and maintenance-dose synthesis; anaphylaxis epi-first order with culprit set and 3.54, 2.29, 4.86, 3.58 odds; stress-driven effector-down/suppressor-up metastatic niche with dormant-micrometastasis waking; and nodal clearance-versus-preservation equipoise.^{[1][2][5][6][7][8][9][10][14][15][16][11][12][3][4][17][18][19][20][21][22][23][24][25][26][27][28][29][30][31][32][34][35][36][37][38][39][41][40]}

Transfusion immunomodulation with storage, leukocyte and cancer-recurrence detail belongs to transfusion-coagulation; immunonutrition formulas and feeding regimens to surgical-nutrition; wound-phase macrophage detail and closure decisions to wound-healing; SSI bundles and antimicrobial choice to surgical-infection-antimicrobials; checkpoint science, hallmarks and tumour markers to oncology-tumour-biology; fluids, pressures and electrolytes to fluids-electrolytes and acid-base-balance; resuscitation, pressors and massive-transfusion triggers to shock, trauma and haemostasis topics; sepsis bundles and antimicrobials to sepsis and shock topics; rejection grades, drug dosing and desensitisation to transplant topics; and assay ordering, immunotherapy prescribing and chemotherapy regimens to disease and pharmacology topics — this topic claims only the general principles above with the numbers named beside them.^{[2][11][21][23][31][40]}

Exam Pearls — the One-Liners That Score

• Kehlet 1997: stress response is the key morbidity factor excluding technique failure; cascades named; no single fix, multimodal reduction only.^[1]
• Proportionality: immune disorder scales with trauma extent, cancer background, infection, nutrition; cancer surgery runs SIRS plus CARS together.^[2]
• Laparoscopy preserves systemic (DTH, lymphocyte antigens) while CO2 quiets peritoneal (TNF, phagocytosis) immunity.^[5]
• Regional blunts cortisol/catecholamines with less suppression; volatile NK concern stated with insufficient-evidence humility.^[6]
• Dysautonomia (sympathetic up, vagal down) drives immunosuppression via weak cholinergic anti-inflammatory braking — balance is the prospect.^[7]
• Brain-mediated depression: HPA plus sympathetic plus catecholamine-IL-10 monocyte switch beside glucocorticoids.^[8]
• TNF/IL-1/IL-6 provision fuel and hormones first, drive sepsis syndrome in massive release second; cascade drugs need proof first.^[9]
• Severity first, cascades second; shocked gut bridges non-infectious to infectious SIRS.^[10]
• LPS fires kallikrein-kinin with coagulation, fibrinolysis and complement; plasma LPS tracks MODS; monitor early.^[14]
• C1-INH treats hereditary angio-oedema, consumed in inflammation with sepsis/reperfusion/BMT/lung/burn/IL-2 signals; sCR1 still awaited in humans.^[25]
• One system: dendritic phenotype decides naive-T fate; complement joins humoral memory; coordination is vital.^[26]
• Six-step MHC-I-to-CD8/MHC-II-to-CD4 ladder; HLA is the fifty-year surveillance platform.^[27][28]
• M1 (LPS/Th1; IL-1beta, IL-6, IL-12, IL-23, TNF-alpha) versus M2 (IL-4/IL-13; IL-10, TGF-beta); balance governs organ fate.^[29]
• Four orderly stages: recruit, differentiate-activate, convert-to-suppressive, restore homeostasis.^[30]
• Bone 1997 CARS: counter-regulation with nosocomial price, reprogramming without global defect, primed tissues, compartmentalised silencing.^[15]
• Timing plus magnitude decides outcome; SIRS kills organisms, CARS restores homeostasis.^[16]
• First plus second hits; imbalance injures; trials failed but protocols and damage control worked.^[11]
• SIRS on monocytes then CARS quench; deviation means MOF — precise and fragile.^[12]
• No MODS rescue exists: prevent early; interferon, G-CSF, PGE2-blockade, pentoxifylline are candidates only.^[3]
• Immediate generalised post-op immunosuppression implicates sepsis, metastasis and adjuvant dependence.^[4]
• PICS past day 10 replaces late MOF; rebalance plus nutrition and physio is the therapy; self-sufficiency rare.^[17]
• HLA-DR depression is the commonest danger marker (with ex-vivo TNF fall); predicts but never yet guides.^[18]
• Sepsis is a balance race; phase-matched biomarker-guided immunotherapy is the horizon after blanket failures.^[19]
• Hyperinflammation and suppression coincide; endotypes stratify; translation is the challenge.^[20]
• Dysregulated activation-plus-suppression defines sepsis; variability individualises treatment by rapid biomarkers.^[21]
• Immunocompromised sepsis presents atypically, tests differ, recognition lags — include these patients in trials.^[22]
• Abdominal sepsis: WBC/CRP/PCT routine; TNF/IL-6/HMGB1/presepsin studied-not-routine; source control plus surgery cures.^[23]
• DAMP/SAMP window: treat pathological concentrations only; SIRS-inhibit, chronic-SAMP, CARS-unsuppress, vaccine-induce.^[24]
• DMARDs continue, steroids minimise, biologics balance against flare, APS bridges.^[32]
• True insufficiency gets stress hydrocortisone; 5-mg-month suppression threshold; blanket cover inappropriate; undiagnosed AI debuts under stress.^[34]
• Steroid evidence: no guideline, hyperglycaemia/infection/wound harm, 2 RCTs with 37 patients, no conclusion possible.^[35]
• Six-decade supraphysiologic standard yields to maintenance-dose continuation with hypotension watch.^[36]
• Anaphylaxis culprits: antibiotics, blockers, dyes, latex, disinfectants; under-recognised and life-threatening.^[37]
• Triad hypotension/tachycardia/bronchospasm is nonspecific; vasopressor-resistance, hypovolaemia and timing support it; epi-first without waiting for rash.^[38]
• Allergy odds: drugs 3.54, food 2.29, history 4.86, atopy 3.58 raise incidence, not severity.^[39]
• Stress downregulates four effectors (neutrophils, macrophages, NK, CTL) and upregulates two suppressors (Treg, MDSC) into the niche.^[41]
• Surgery wakes dormant micrometastases through stress hormones plus healing immunosuppression, vessels and remodelling.^[42]
• Nodes coordinate anti-tumour immunity and ICI response (dMMR/MSI-H most); yield-survival link confounded; equipoise with stratified trials to come.^[40]

Gentile 2012 redraws the timeline: ICU stays beyond about 10 days with persistent immune dysfunction are PICS, not classic late MOF.^[17]

References42ShowHide

1. [1]Kehlet H, et al. Multimodal approach to control postoperative pathophysiology and rehabilitation. Br J Anaesth, 1997.PMID 9175983
2. [2]Dąbrowska AM, et al. The immune response to surgery and infection. Cent Eur J Immunol, 2014.PMID 26155175
3. [3]Ni Choileain N, et al. Cell response to surgery. Arch Surg, 2006.PMID 17116807
4. [4]Hogan BV, et al. Surgery induced immunosuppression. Surgeon, 2011.PMID 21195330
5. [5]Buunen M, et al. Stress response to laparoscopic surgery: a review. Surg Endosc, 2004.PMID 15136930
6. [6]Iwasaki M, et al. Anesthesia, surgical stress, and "long-term" outcomes. Acta Anaesthesiol Taiwan, 2015.PMID 26235899
7. [7]Pan WT, et al. Effect of perioperative autonomic nervous system imbalance on surgical outcomes: a systematic review. Br J Anaesth, 2025.PMID 40615330
8. [8]Woiciechowsky C, et al. Mechanisms of brain-mediated systemic anti-inflammatory syndrome causing immunodepression. J Mol Med (Berl), 1999.PMID 10619437
9. [9]Molloy RG, et al. Cytokines, sepsis and immunomodulation. Br J Surg, 1993.PMID 8472134
10. [10]Schlag G, et al. Mediators of injury and inflammation. World J Surg, 1996.PMID 8662127
11. [11]Keel M, et al. Pathophysiology of polytrauma. Injury, 2005.PMID 15910820
12. [12]Laudanski K, et al. Monocyte-related immunopathologies in trauma patients. Arch Immunol Ther Exp (Warsz), 2005.PMID 16088316
13. [13]Oberholzer A, et al. Sepsis syndromes: understanding the role of innate and acquired immunity. Shock, 2001.PMID 11508871
14. [14]Aasen AO, et al. Mediator responses in surgical infections. Surg Infect (Larchmt), 2006.PMID 16895500
15. [15]Adib-Conquy M, et al. Compensatory anti-inflammatory response syndrome. Thromb Haemost, 2009.PMID 19132187
16. [16]Ward NS, et al. The compensatory anti-inflammatory response syndrome (CARS) in critically ill patients. Clin Chest Med, 2008.PMID 18954697
17. [17]Gentile LF, et al. Persistent inflammation and immunosuppression: a common syndrome and new horizon for surgical intensive care. J Trauma Acute Care Surg, 2012.PMID 22695412
18. [18]Galbraith N, et al. The Significance and Challenges of Monocyte Impairment: For the Ill Patient and the Surgeon. Surg Infect (Larchmt), 2016.PMID 26958709
19. [19]Hotchkiss RS, et al. Sepsis-induced immunosuppression: from cellular dysfunctions to immunotherapy. Nat Rev Immunol, 2013.PMID 24232462
20. [20]Wiersinga WJ, et al. Immunopathophysiology of human sepsis. EBioMedicine, 2022.PMID 36470832
21. [21]Singer M, et al. Sepsis. Lancet, 2026.PMID 41765030
22. [22]Deinhardt-Emmer S, et al. Sepsis in patients who are immunocompromised: diagnostic challenges and future therapies. Lancet Respir Med, 2025.PMID 40409328
23. [23]Peksöz R, et al. A Focus on Intra-Abdominal Sepsis with Biomarkers: A Literature Review. Eurasian J Med, 2022.PMID 36655448
24. [24]Land WG, et al. Use of DAMPs and SAMPs as Therapeutic Targets or Therapeutics: A Note of Caution. Mol Diagn Ther, 2020.PMID 32248387
25. [25]Asghar SS, et al. Therapeutic inhibition of the complement system. Y2K update. Front Biosci, 2000.PMID 10966868
26. [26]George AJT, et al. Interactions Between the Innate and Adaptive Immune Responses. Adv Exp Med Biol, 2025.PMID 40622548
27. [27]Pishesha N, et al. A guide to antigen processing and presentation. Nat Rev Immunol, 2022.PMID 35418563
28. [28]Dendrou CA, et al. HLA variation and disease. Nat Rev Immunol, 2018.PMID 29292391
29. [29]Shapouri-Moghaddam A, et al. Macrophage plasticity, polarization, and function in health and disease. J Cell Physiol, 2018.PMID 29319160
30. [30]Murray PJ, et al. Protective and pathogenic functions of macrophage subsets. Nat Rev Immunol, 2011.PMID 21997792
31. [31]Desai DM, et al. Perioperative management of special populations: immunocompromised host (cancer, HIV, transplantation). Surg Clin North Am, 2005.PMID 16326207
32. [32]Akkara Veetil BM, et al. Perioperative care for patients with rheumatic diseases. Nat Rev Rheumatol, 2011.PMID 22083219
33. [33]Dabo-Trubelja A, et al. Care of the immunocompromised cancer patient in the perioperative period: Narrative review. Indian J Anaesth, 2025.PMID 41395144
34. [34]Woodcock T, et al. Guidelines for the management of glucocorticoids during the peri-operative period for patients with adrenal insufficiency: Guidelines from the Association of Anaesthetists, the Royal College of Physicians and the Society for Endocrinology UK. Anaesthesia, 2020.PMID 32017012
35. [35]Groleau C, et al. Perioperative corticosteroid administration: a systematic review and descriptive analysis. Perioper Med (Lond), 2018.PMID 29977522
36. [36]Kelly KN, et al. Perioperative stress-dose steroids. Clin Colon Rectal Surg, 2013.PMID 24436668
37. [37]Pitlick MM, et al. Perioperative Anaphylaxis. Immunol Allergy Clin North Am, 2022.PMID 34823744
38. [38]Ma M, et al. Perioperative anaphylaxis: an update on pathophysiology, diagnosis, and management. Can J Anaesth, 2025.PMID 40244358
39. [39]Zhang P, et al. Relationship between perioperative anaphylaxis and history of allergies or allergic diseases: A systematic review and meta-analysis with meta-regression. J Clin Anesth, 2024.PMID 38387242
40. [40]Stratton M, et al. Rethinking lymphadenectomy in the immunotherapy era of colorectal cancer: A hypothesis-generating perspective. Colorectal Dis, 2026.PMID 42396616
41. [41]Yang F, et al. Surgical stress induced tumor immune suppressive environment. Carcinogenesis, 2024.PMID 38366618
42. [42]Shurin MR, et al. Neuroimmune Regulation of Surgery-Associated Metastases. Cells, 2021.PMID 33672617